Patents by Inventor Takeru Fujii
Takeru Fujii has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240134361Abstract: A use resource setting device includes a control unit and a storage unit. The storage unit holds resource type information, work time information, and production plan information. A use resource setting method includes the control unit predicting calculation accuracy of required time of work in a use resource plan in which one or more resources are allocated to work in each process of producing the product, based on the resource type information, the work time information, and the production plan information, and, predicting an evaluation index for producing the product when the use resource plan is adopted, based on the use resource plan, the work time information, and the production plan information. The predicting of the evaluation index includes predicting a variation in the evaluation index based on the calculation accuracy of the required time of the work in the use resource plan by the control unit.Type: ApplicationFiled: October 17, 2023Publication date: April 25, 2024Applicant: Hitachi Systems, Ltd.Inventors: Takeru DOAN, Norisuke FUJII, Koichi Hattori
-
Patent number: 8323693Abstract: There is provided an external preparation for wounds which has novel usability in treating skin damages accompanied by a large amount of exudation such as bedsores, skin ulcers, and burns, and yet has such advantages as observed in conventional medicines having been employed in treating these wounds. The external preparation for wounds comprises a water-soluble polymer and a crosslinking agent, and has powdery/granular or ointment form. After absorbing an exudation, the preparation undergoes phase transition from a sol to a gel by the action of ingredient of the preparation, and thus exhibits actions of adsorbing and eliminating necrotic tissues, and protecting the wounded parts. Subsequently, it can continuously absorb the exudation. After being used, it can be easily separated substantially as a mass, thereby exhibiting high therapeutic effects and usability.Type: GrantFiled: March 12, 2003Date of Patent: December 4, 2012Assignees: Medrx Co., Ltd., Nippon Shinyaku Co., Ltd.Inventors: Hidetoshi Hamamoto, Keiko Yamasaki, Hideakira Yokoyama, Akihiko Hirata, Takeru Fujii
-
Patent number: 8207111Abstract: The object of the present invention is to provide a method for treating muscular dystrophy. The method for treating muscular dystrophy according to the present invention is characterized in comprising a step of administering a caldecrin.Type: GrantFiled: May 19, 2010Date of Patent: June 26, 2012Inventors: Akito Tomomura, Mineko Tomomura, Akihiko Hirata, Takeru Fujii
-
Publication number: 20110159035Abstract: It is an objective of the present invention to provide a non-invasive transdermal immunizing technology by which inflammation and lump do not appear at the skin unlike conventional transdermal immunizing methods with subcutaneous administration and the development amount of antibody in serum is increased. The S/O type transdermal immunizing agent according to the present invention comprises an antigen-surfactant complex and an oil phase; wherein the antigen is covered with the surfactant in the complex; the complex is in a solid state; and the complex is dissolved or dispersed in the oil phase.Type: ApplicationFiled: August 1, 2008Publication date: June 30, 2011Inventors: Masahiro Goto, Noriho Kamiya, Akihiko Hirata, Takeru Fujii
-
Publication number: 20110015116Abstract: The object of the present invention is to provide a method for treating muscular dystrophy. The method for treating muscular dystrophy according to the present invention is characterized in comprising a step of administering a caldecrin.Type: ApplicationFiled: May 19, 2010Publication date: January 20, 2011Inventors: Akito Tomomura, Mineko Tomomura, Akihiko Hirata, Takeru Fujii
-
Publication number: 20100298447Abstract: This invention is intended to improve the solubility and permeability of low-solubility drugs, including drugs hardly soluble in water, classified as Class 2 or 4 in accordance with BCS by modifying such drugs into S/W, S/O, or S/O/W preparations. The S/W, S/O, or S/O/W preparations of low-solubility drugs of this invention are prepared by a method for preparing a composite of a low-solubility drug and surfactant by introducing air or nonflammable gas into the gas phase in the upper portion of a liquid level of the dispersion, dissolution, and emulsification tanks, respectively, at a pressure of 1 to 10 atm.Type: ApplicationFiled: October 29, 2008Publication date: November 25, 2010Inventors: Takeru Fujii, Eiji Hayakawa, Akihiko Hirata
-
Publication number: 20090238846Abstract: The present invention provides an external preparation which can improve a skin permeability of a hydrophilic medicine such as NSAID so that the medicine can act directly on a diseased area without passing through gastrointestinal tract or mucosa. The S/O type external preparation external preparation excellent in percutaneous absorbability of the present invention comprises a medicine-containing complex dissolved or dispersed in an oil phase, wherein the complex contains a hydrophilic medicine covered with a surfactant and is in a form of a solid.Type: ApplicationFiled: August 31, 2005Publication date: September 24, 2009Applicant: ASPION CO., LTD.Inventors: Takeru Fujii, Akihiko Hirata, Masahiro Goto, Noriho Kamiya
-
Publication number: 20090053788Abstract: The object of the present invention is to provide a drug having therapeutic effect on muscular dystrophy without lowering renal function. The therapeutic drug for muscular dystrophy of the present invention comprises a caldecrin or a caldecrin gene.Type: ApplicationFiled: October 1, 2007Publication date: February 26, 2009Applicant: ASPION CO., LTD.Inventors: Akito Tomomura, Mineko Tomomura, Akihiko Hirata, Takeru Fujii
-
Publication number: 20080202046Abstract: A sash window assembly includes a face material provided in an opening section open to an indoor and outdoor side, a frame section provided within the opening section, and beads attached to the frame section with the ends of the beads angled and butted against one another, the beads for pressing upon the face material from one of the indoor and outdoor directions, wherein each of the beads includes a first engaging section and a second engaging section, the first engaging section engaging with the frame section at a front-side in a movement direction, the second engaging section engaging with the frame further toward a rear-side in the movement direction than the first engaging section, when the bead is moved in the movement direction along a depth direction; the frame section includes a first engaging projection that engages with the first engaging section, a second engaging projection that engages with the second engaging section, and a recess provided between the first engaging projection and the second enType: ApplicationFiled: February 7, 2008Publication date: August 28, 2008Applicant: YKK AP INC.Inventor: Takeru Fujii
-
Patent number: 7291337Abstract: The peptide in this invention is a peptide having affinity to gp120 represented by Formula (1): H-A1-A2-A3-A4-A5-R(SEQ ID No. 1) (in the formula, H means hydrogen, A1 is aspartic acid, lysine, valine, glutamic acid, glycine, asparagine, or tyrosine residue, A2 is valine, aspartic acid, tryptophan, lysine, phenylalanine, isoleucine, leucine, or tyrosine residue, A3 is lysine, valine, aspartic acid, arginine, alanine, or tryptophan residue, A4 is alanine, tryptophan, or glycine residue, A5 is glycine, alanine, valine, leucine, isoleucine, serine, threonine, methionine, asparagine, glutamine, histidine, lysine, arginine, phenylalanine, tryptophan, proline, or tyrosine residue, R is OH derived from carboxyl group or NH2 derived from acid amide group). The above peptide has an affinity to gp120 of the HIV envelope protein and is superior in stability.Type: GrantFiled: August 3, 2004Date of Patent: November 6, 2007Assignee: Aspion Co., Ltd.Inventors: Takeru Fujii, Hideakira Yokoyama, Hidetoshi Hamamoto
-
Publication number: 20070207138Abstract: The present invention provides a pharmaceutical preparation that significantly reduces leakage of a low-molecule medicine in a strong acidic environment, while allowing release of the low-molecule medicine in the enteric canal or the like which is in a weak acidic to neutral environment. The S/O type pharmaceutical preparation of the present invention is characterized in comprising a medicine-containing complex dissolved or dispersed in an oil phase, wherein the complex contains a mixture and a surfactant, the mixture is covered by the surfactant, and the mixture contains a hydrophilic low molecule medicine, and a hydrophilic medicine-leakage-suppressive protein and/or a medicine-leakage-suppressive polysaccharide.Type: ApplicationFiled: March 31, 2005Publication date: September 6, 2007Applicant: ASPION CO., LTD.Inventors: Masahiro Goto, Noriho Kamiya, Aklhiko Hirata, Takeru Fujii
-
Publication number: 20070053939Abstract: The invention provides a biguanide drug-containing jelly preparation of which discomfort upon administration is decreased by the control of its harshness or bitterness. In addition, the preparation has stability and excellent ability for releasing a drug in the digestive tract. The biguanide drug-containing jelly preparation of the invention is characterized by comprising a biguanide drug, an inorganic acid, and a water-soluble polymer. The jelly preparation of the invention is excellent in both stability and ability for releasing a drug, which are usually incompatible characters, particularly by the action of the inorganic acid.Type: ApplicationFiled: October 15, 2004Publication date: March 8, 2007Inventors: Hideakira Yokoyama, Akihiko Hirata, Hidetoshi Hamamoto, Masaki Ishibashi, Keiko Yamasaki, Takeru Fujii
-
Publication number: 20050118269Abstract: There is provided an external preparation for wounds which has novel usability in treating skin damages accompanied by a large amount of exudation such as bedsores, skin ulcers, and burns, and yet has such advantages as observed in conventional medicines having been employed in treating these wounds. The external preparation for wounds comprises a water-soluble polymer and a crosslinking agent, and has powdery/granular or ointment form. After absorbing an exudation, the preparation undergoes phase transition from a sol to a gel by the action of ingredient of the preparation, and thus exhibits actions of adsorbing and eliminating necrotic tissues, and protecting the wounded parts. Subsequently, it can continuously absorb the exudation. After being used, it can be easily separated substantially as a mass, thereby exhibiting high therapeutic effects and usability.Type: ApplicationFiled: March 12, 2003Publication date: June 2, 2005Inventors: Hidetoshi Hamamoto, Keiko Yamasaki, Hideakira Yokoyama, Akihiro Hirata, Takeru Fujii
-
Publication number: 20050089577Abstract: It is intended to provide a liquid matrix for medicinal use in which medicine can be easily solubilized, dispersed or suspended and which can be easily swallowed because of being liquid, has favorable working properties in sterilization and so on and a high stability, also exhibits an effect of masking bitterness, and gels in vivo so as to control the release speed of the medicine, and liquid oral preparations using the same. Namely, a liquid matrix which is a liquid assistant for facilitating swallowing medicine characterized in comprising a water-soluble polymer gelling under acidic conditions, and the breaking stress of the gel is about 3.00×103 N/m2 or more. Liquid oral preparations have favorable slow release properties even though being a liquid.Type: ApplicationFiled: March 3, 2003Publication date: April 28, 2005Inventors: Hideakira Yokoyama, Akihiko Hirata, Hidetoshi Hamamoto, Keiko Yamasaki, Takeru Fujii
-
Publication number: 20050004040Abstract: The peptide in this invention is a peptide having affinity to gp120 represented by Formula (1): H-A1-A2-A3-A4-A5-R (in the formula, H means hydrogen, A1 is aspartic acid, lysine, valine, glutamic acid, glycine, asparagine, or tyrosine residue, A2 is valine, aspartic acid, tryptophan, lysine, phenylalanine, isoleucine, leucine, or tyrosine residue, A3 is lysine, valine, aspartic acid, arginine, alanine, or tryptophan residue, A4 is alanine, tryptophan, or glycine residue, A5 is glycine, alanine, valine, leucine, isoleucine, serine, threonine, methionine, asparagine, glutamine, histidine, lysine, arginine, phenylalanine, tryptophan, proline, or tyrosine residue, R is OH derived from carboxyl group or NH2 derived from acid amide group). The above peptide has an affinity to gp120 of the HIV envelope protein and is superior in stability.Type: ApplicationFiled: August 3, 2004Publication date: January 6, 2005Inventors: Takeru Fujii, Hideakira Yokoyama, Hidetoshi Hamamoto
-
Patent number: 6827939Abstract: The peptide in this invention is a peptide having affinity to gp120 represented by H-A1-A2-A3-A4-A5-R (SEQ ID No. 1) Formula (1) (in the formula, H means hydrogen, A1 is aspartic acid, lysine, valine, glutamic acid, glycine, asparagine, or tyrosine residue, A2 is valine, aspartic acid, tryptophan, lysine, phenylalanine, isoleucine, leucine, or tyrosine residue, A3 is lysine, valine, aspartic acid, arginine, alanine, or tryptophan residue, A4 is alanine, tryptophan, or glycine residue, A5 is glycine, alanine, valine, leucine, isoleucine, serine, threonine, methionine, asparagine, glutamine, histidine, lysine, arginine, phenylalanine, tryptophan, proline, or tyrosine residue, R is OH derived from carboxyl group or NH2 derived from acid amide group).Type: GrantFiled: January 11, 2001Date of Patent: December 7, 2004Assignee: MedRx Co., Ltd.Inventors: Takeru Fujii, Hideakira Yokoyama, Hidetoshi Hamamoto
-
Publication number: 20020052469Abstract: The peptide in this invention is a peptide having affinity to gp120 represented by Formula (1): H-A1-A2-A3-A4-A5-RType: ApplicationFiled: January 11, 2001Publication date: May 2, 2002Inventors: Takeru Fujii, Hideakira Yokoyama, Hidetoshi Hamamoto
-
Patent number: 6060254Abstract: A viral agglutination test agent and a virus test kit containing the agent, which can directly and sensitively detect viruses in blood without using the anti-viral antibody formed in the blood of patients with viral infections.Type: GrantFiled: April 21, 1998Date of Patent: May 9, 2000Inventors: Takeru Fujii, Hideakira Yokoyama, Hidetoshi Hamamoto
-
Patent number: 5840685Abstract: Pharmaceutical compositions of matter adapted for intravaginal administration comprise a biologically active polypeptide, an absorption promoter, such as an anionic and/or nonionic surfactant or a nonionic surfactant and an aliphatic carboxylic acid, optionally an animal and/or vegetable protein and a nontoxic pharmaceutically acceptable carrier or diluent therefor, in a formulation suitable for intravaginal administration. Preferred compositions comprise calcitonin as the biologically active polypeptide. Preferred absorption promoters are anionic surfactants, e.g., sodium lauryl sulfate, and the combination absorption promoter of a nonionic surfactant and a medium chain aliphatic carboxylic acid or its salt, e.g. polyoxyethylenealkylphenylether and a medium chain aliphatic carboxylic acid.Type: GrantFiled: June 15, 1992Date of Patent: November 24, 1998Assignee: Teikoku Seiyaku Co., Ltd.Inventors: Takeru Fujii, Seiichi Sako, Shigeyuki Takama, Toru Hibi, Akiya Yamada
-
Patent number: 5824646Abstract: Pharmaceutical compositions of matter adapted for intravaginal administration comprise a biologically active polypeptide, an absorption promoter, such as an anionic and/or nonionic surfactant or a nonionic surfactant and an aliphatic carboxylic acid, optionally an animal and/or vegetable protein and a nontoxic pharmaceutically acceptable carrier or diluent therefor, in a formulation suitable for intravaginal administration. Preferred compositions comprise calcitonin as the biologically active polypeptide. Preferred absorption promoters are anionic surfactants, e.g., sodium lauryl sulfate, and the combination absorption promoter of a nonionic surfactant and a medium chain aliphatic carboxylic acid or its salt, e.g. polyoxyethylenealkylphenylether and a medium chain aliphatic carboxylic acid.Type: GrantFiled: November 17, 1997Date of Patent: October 20, 1998Assignee: Teikoku Seiyaku Co., Ltd.Inventors: Takeru Fujii, Seiichi Sako, Shigeyuki Takama, Toru Hibi, Akiya Yamada